Pharmerit’s study on cost-effectiveness of a treatment in postmenopausal women with early breast cancer accepted in ASCO

Pharmerit is pleased to announce that its research assessing the cost effectiveness of a pharmaceutical treatment in postmenopausal women with early breast cancer in US has been accepted in ASCO. The cost-effectiveness analysis used a Markov style state transition model to simulate the disease progression and survival for a hypothetical cohort of postmenopausal women with early breast cancer. Costs and utility were estimated with literature-based evidence. Transition probabilities were derived from a randomized clinical trial.

Professor Ben van Hout gives inaugural ScHARR lecture "Who Shall NOT Live" 

Pharmerit International congratulates Ben van Hout, PhD, Professor of Health Economics at the University of Sheffield in the department of Health Economics and Decision Sciences, for his inaugural lecture on Tuesday, 28 February,2011 in Mappin Hall. Professor van Hout’s lecture topic was  provocatively titled “Who Shall NOT Live?” It addressed broad philosophical questions related to the effect of prioritizing health care spending within health care, and how these choices results in some 'winners' and some 'losers'.

Read more